Diethylstilboestrol for the treatment of prostate cancer: past, present and future

@article{Turo2014DiethylstilboestrolFT,
  title={Diethylstilboestrol for the treatment of prostate cancer: past, present and future},
  author={R. Turo and M. Smolski and R. Esler and Magda L Kujawa and S. Bromage and N. Oakley and A. Adeyoju and S. Brown and R. Brough and A. Sinclair and G. Collins},
  journal={Scandinavian Journal of Urology},
  year={2014},
  volume={48},
  pages={14 - 4}
}
  • R. Turo, M. Smolski, +8 authors G. Collins
  • Published 2014
  • Medicine
  • Scandinavian Journal of Urology
  • Abstract The aim of this review was to discuss the most recent data from current trials of diethylstilboestrol (DES) to identify its present role in advanced prostate cancer treatment as new hormonal therapies emerge. The most relevant clinical studies using DES in castration-refractory prostate cancer (CRPC) were identified from the literature. The safety, efficacy, outcomes and mechanisms of action are summarized. In the age of chemotherapy this review highlights the efficacy of oestrogen… CONTINUE READING
    23 Citations

    Topics from this paper

    Paper Mentions

    News Article
    The resurgence of estrogens in the treatment of castration-resistant prostate cancer
    • 1
    Estrogens and prostate cancer
    • 17
    • PDF
    Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.
    • 406
    • PDF

    References

    SHOWING 1-10 OF 102 REFERENCES
    Hormonal therapy for prostate cancer: past, present and future
    • 18
    Diethylstilbestrol (DES) retains activity and is a reasonable option in patients previously treated with docetaxel for castration-resistant prostate cancer.
    • 26
    Low-dose diethylstilbestrol for the treatment of advanced prostate cancer.
    • 28
    Optimizing the use of docetaxel in men with castration-resistant metastatic prostate cancer
    • 18
    • PDF
    Experience with low-dose oestrogen in the treatment of advanced prostate cancer: a personal view.
    • M. Bishop
    • Medicine
    • British journal of urology
    • 1996
    • 28
    Phase III randomised study of zoladex versus stilboestrol in the treatment of advanced prostate cancer.
    • 46